This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olsen, A. Articles by Tjønneland, A. Search for Related Content PubMed PubMed Citation Articles by Olsen, A. Articles by Tjønneland, A.

Plasma Enterolactone and Breast Cancer Incidence by Estrogen Receptor Status

¹ Institute of Cancer Epidemiology, Danish Cancer Society; ² Institute of Public Health, University of Copenhagen; ³ Danish Breast Cancer Co-operative Group, Rigshospitalet, Copenhagen, Denmark; ⁴ Department of Animal Nutrition and Physiology, Research Centre Foulum, Tjele, Denmark; and ⁵ Department of Clinical Epidemiology, Aalborg Hospital and Aarhus University Hospital, and Department of Epidemiology and Social Medicine, University of Aarhus, Aarhus, Denmark

Requests for reprints: Anja Olsen, Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark. Phone: 45-35257606; Fax: 45-35257731. E-mail: anja{at}cancer.dk

The phytoestrogen enterolactone has been hypothesized to prevent breast cancer. Because one of the biological effects of enterolactone is probably estrogenic, it is possible that the preventive effect on breast cancer differs with the estrogen receptor (ER) status of the tumor. The objective of this study was to investigate whether high plasma levels of enterolactone are associated with breast cancer risk and whether the ER status of the tumor influences this relation. The cohort study Diet, Cancer and Health included 29,785 women, ages 50 to 64 years, between 1993 and 1997. Information about diet and life-style factors was obtained by questionnaire, and blood was drawn from each participant. We matched 381 postmenopausal breast cancer cases to 381 controls and analyzed the concentration of enterolactone in plasma with a time-resolved fluoroimmunoassay. Associations between plasma concentrations of enterolactone and breast cancer were analyzed by logistic regression. The incidence rate ratio (IRR) for all breast cancer was 0.93 [95% confidence interval (CI), 0.86-1.01] per 20 nmol/L higher plasma concentration of enterolactone. For ER-positive cancers (n=273) only a weak association was seen (IRR, 0.97; 95% CI, 0.88-1.06), whereas for ER-negative cancers (n = 80; IRR, 0.71; 95% CI, 0.53-0.94) a protective effect was seen per 20 nmol/L higher plasma enterolactone. In accordance with earlier research, we found a tendency toward a lower risk for breast cancer with higher concentrations of enterolactone, which was restricted almost entirely to ER-negative breast cancer.

This article has been cited by other articles:

				E. Sonestedt, S. Borgquist, U. Ericson, B. Gullberg, H. Olsson, H. Adlercreutz, G. Landberg, and E. Wirfalt Enterolactone Is Differently Associated with Estrogen Receptor {beta}-Negative and -Positive Breast Cancer in a Swedish Nested Case-Control Study Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3241 - 3251. [Abstract] [Full Text] [PDF]

				M. Hedelin, M. Lof, M. Olsson, H. Adlercreutz, S. Sandin, and E. Weiderpass Dietary Phytoestrogens Are Not Associated with Risk of Overall Breast Cancer But Diets Rich in Coumestrol Are Inversely Associated with Risk of Estrogen Receptor and Progesterone Receptor Negative Breast Tumors in Swedish Women J. Nutr., May 1, 2008; 138(5): 938 - 945. [Abstract] [Full Text] [PDF]

				A. Kuijsten, P. C. H. Hollman, H. C. Boshuizen, M. N. C. P. Buijsman, P. van 't Veer, F. J. Kok, I. C. W. Arts, and H. B. Bueno-de-Mesquita Plasma Enterolignan Concentrations and Colorectal Cancer Risk in a Nested Case-Control Study Am. J. Epidemiol., March 15, 2008; 167(6): 734 - 742. [Abstract] [Full Text] [PDF]

				M. S. Touillaud, A. C. M. Thiebaut, A. Fournier, M. Niravong, M.-C. Boutron-Ruault, and F. Clavel-Chapelon Dietary Lignan Intake and Postmenopausal Breast Cancer Risk by Estrogen and Progesterone Receptor Status J Natl Cancer Inst, March 21, 2007; 99(6): 475 - 486. [Abstract] [Full Text] [PDF]

				M. Verheus, C. H. van Gils, L. Keinan-Boker, P. B. Grace, S. A. Bingham, and P. H.M. Peeters Plasma Phytoestrogens and Subsequent Breast Cancer Risk J. Clin. Oncol., February 20, 2007; 25(6): 648 - 655. [Abstract] [Full Text] [PDF]

				A. Kuijsten, I. C.W. Arts, P. C.H. Hollman, P. van't Veer, and E. Kampman Plasma enterolignans are associated with lower colorectal adenoma risk. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1132 - 1136. [Abstract] [Full Text] [PDF]

				J. A. Baker, G. P. Beehler, A. C. Sawant, V. Jayaprakash, S. E. McCann, and K. B. Moysich Consumption of Coffee, but Not Black Tea, Is Associated with Decreased Risk of Premenopausal Breast Cancer J. Nutr., January 1, 2006; 136(1): 166 - 171. [Abstract] [Full Text] [PDF]

				A. Kuijsten, I. C. W. Arts, P. van't Veer, and P. C. H. Hollman The Relative Bioavailability of Enterolignans in Humans Is Enhanced by Milling and Crushing of Flaxseed J. Nutr., December 1, 2005; 135(12): 2812 - 2816. [Abstract] [Full Text] [PDF]

				A. Stuedal, I. T. Gram, Y. Bremnes, H. Adlercreutz, M. B. Veierod, and G. Ursin Plasma Levels of Enterolactone and Percentage Mammographic Density among Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2154 - 2159. [Abstract] [Full Text] [PDF]